Long-lasting responses after discontinuation of nivolumab treatment for reasons other than tumor progression in patients with previously treated, advanced non-small cell lung cancer-Reference-Cited by-同舟云学术

Long-lasting responses after discontinuation of nivolumab treatment for reasons other than tumor progression in patients with previously treated, advanced non-small cell lung cancer

Published:2019-11-21 Issue:1 Volume:39 Page:
ISSN:2523-3548
Container-title:Cancer Communications
language:en
Short-container-title:Cancer Commun

Author:

Kimura Hideharu,Araya Tomoyuki,Yoneda Taro,Shirasaki Hiroki,Kurokawa Koji,Sakai Tamami,Koba Hayato,Tambo Yuichi,Nishikawa Shingo,Sone Takashi,Kasahara Kazuo

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

http://link.springer.com/content/pdf/10.1186/s40880-019-0423-3.pdf

Reference10 articles.

1. Brahmer J, Reckamp KL, Baas P, Crinò L, Eberhardt WE, Poddubskaya E, et al. Nivolumab versus docetaxel in advanced squamous-cell non–small-cell lung cancer. N Engl J Med. 2015;373:123–35.

2. Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 2015;373:1627–39.

3. The Japan lung cancer society. Surgical treatment. NSCLC. Guidelines for diagnosis and treatment of lung cancer. Tokyo: Kanehara & Co Ltd.; 2016; p. 45–81.

4. Kimura H, Sone T, Murata A, Koba H, Tambo Y, Hara J, et al. Long-lasting shrinkage in tumor mass after discontinuation of nivolumab treatment. Lung Cancer. 2017;108:7–8.

5. Horn L, Spigel DR, Vokes EE, Holgado E, Ready N, Steins M, et al. Nivolumab versus docetaxel in previously treated patients with advanced non-small-cell lung cancer: two-year outcomes from two randomized, open-label, phase III trials (CheckMate 017 and CheckMate 057). J Clin Oncol. 2017;35:3924–33.

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immunotherapy and Radiotherapy for Older Patients with Locally Advanced Non-Metastatic Non-Small-Cell Lung Cancer Who Are Not Candidates for or Decline Surgery and Chemotherapy: A Practical Proposal by the International Geriatric Radiotherapy Group;Cancers;2024-09-09

2. Outcomes of patients with advanced solid tumors who discontinued immune-checkpoint inhibitors: a systematic review and meta-analysis;eClinicalMedicine;2024-07

3. Extending the dosing intervals of nivolumab: model-based simulations in unselected cancer patients;British Journal of Cancer;2024-03-26

4. The efficacy of immune checkpoint inhibitors following discontinuation for long‐term response or toxicity in advanced or metastatic non‐small‐cell lung cancers: A retrospective study;Health Science Reports;2024-01

5. Evaluation of the efficacy and surgical-related safety of neoadjuvant immunochemotherapy in advanced resectable none small cell lung cancer (NSCLC);Frontiers in Oncology;2023-12-22